New data highlightstaletrectinib's impressive efficacy and safety in treating ROS1-positive non–small cell lung cancer, offering hope for patients.
Geoffrey Liu, MD
Advertisement
Geoffrey Liu, MD, is a medical oncologist at Princess Margaret Cancer Center, University of Toronto.
Articles by Geoffrey Liu, MD
Advertisement
Latest Updated Articles
Taletrectinib's Sustained Efficacy in Advanced ROS1-Positive NSCLCPublished: September 8th 2025 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
